UNITED THERAPEUTICS CORP (UTHR) Stock Price, Forecast & Analysis
NASDAQ:UTHR • US91307C1027
UTHR Key Statistics, Chart & Performance
The current stock price of UTHR is 503.9 USD. In the past month the price increased by 7.74%. In the past year, price increased by 57.44%.
UTHR Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to UTHR. When comparing the yearly performance of all stocks, UTHR is one of the better performing stocks in the market, outperforming 85.27% of all stocks.
UTHR Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to UTHR. UTHR gets an excellent profitability rating and is at the same time showing great financial health properties.
UTHR Financial Highlights
Over the last trailing twelve months UTHR reported a non-GAAP Earnings per Share(EPS) of 27.9. The EPS increased by 13.41% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 41.94% | ||
| ROA | 16.94% | ||
| ROE | 18.81% | ||
| Debt/Equity | 0 |
UTHR Forecast & Estimates
21 analysts have analysed UTHR and the average price target is 546.8 USD. This implies a price increase of 8.51% is expected in the next year compared to the current price of 503.9.
For the next year, analysts expect an EPS growth of 5.63% and a revenue growth 5.72% for UTHR
UTHR Ownership
UTHR Latest News, Press Relases and Analysis
UTHR Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.98 | 410.174B | ||
| AMGN | AMGEN INC | 17.23 | 209.016B | ||
| GILD | GILEAD SCIENCES INC | 16.7 | 184.799B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.37 | 126.056B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.83 | 82.638B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 49.7 | 43.982B | ||
| INSM | INSMED INC | N/A | 31.848B | ||
| NTRA | NATERA INC | N/A | 28.947B | ||
| BIIB | BIOGEN INC | 12.61 | 28.152B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About UTHR
Company Profile
United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. The company is headquartered in Silver Spring, Maryland and currently employs 1,305 full-time employees. The firm markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also markets and sells an oncology product, Unituxin (dinutuximab) Injection for the treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin. Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder product.
Company Info
UNITED THERAPEUTICS CORP
1000 Spring St
Silver Spring MARYLAND 20910 US
CEO: Martine A. Rothblatt
Employees: 1305
Phone: 13016089292
UNITED THERAPEUTICS CORP / UTHR FAQ
What does UTHR do?
United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. The company is headquartered in Silver Spring, Maryland and currently employs 1,305 full-time employees. The firm markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also markets and sells an oncology product, Unituxin (dinutuximab) Injection for the treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin. Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder product.
What is the stock price of UNITED THERAPEUTICS CORP today?
The current stock price of UTHR is 503.9 USD. The price increased by 0.06% in the last trading session.
What is the dividend status of UNITED THERAPEUTICS CORP?
UTHR does not pay a dividend.
What is the ChartMill technical and fundamental rating of UTHR stock?
UTHR has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
On which exchange is UTHR stock listed?
UTHR stock is listed on the Nasdaq exchange.
What is the GICS sector and industry of UTHR stock?
UNITED THERAPEUTICS CORP (UTHR) operates in the Health Care sector and the Biotechnology industry.
Can you provide the market cap for UNITED THERAPEUTICS CORP?
UNITED THERAPEUTICS CORP (UTHR) has a market capitalization of 21.70B USD. This makes UTHR a Large Cap stock.